THE DEVELOPMENT OF HYPERTENSIVE NEURORETINOPATHY MODEL ON WISTAR RATS
A model of hypertensive neuroretinopathy was developed on Wistar line rats with administration of non-selective NO-synthase blocker N-nitro-L-arginine methyl ester (L-NAME) in a dose 12.5 mg/kg within 28 days on the background of single increased intraocular pressure (IOP) to 110 mmHg. As a result o...
Main Authors: | Anna Peresypkina, Alexandr Dolzhikov, Viktoriya Gubareva, Elena Levkova, Anna Shabelnikova |
---|---|
Format: | Article |
Language: | English |
Published: |
Pensoft Publishers
2017-03-01
|
Series: | Research Results in Pharmacology |
Subjects: | |
Online Access: | https://rrpharmacology.pensoft.net/article/31046/download/pdf/ |
Similar Items
-
CORRECTION OF HYPERTENSIVE NEURORETINOPATHY BY DIMETHYLAMINOETHANOL DERIVATIVE 7-16 IN EXPERIMENT
by: A. A. PERESYPKINA, et al.
Published: (2018-02-01) -
CORRECTION OF RETINAL ANGIOPATHY OF HYPERTENSIVE TYPE BY MINOXIDIL, SILDENAFIL IN EXPERIMENT
by: Anna Peresypkina, et al.
Published: (2016-12-01) -
Acute macular neuroretinopathy following Pfizer-BioNTech COVID-19 vaccination
by: Daniel A. Valenzuela, et al.
Published: (2021-12-01) -
Acute macular neuroretinopathy associated with acute promyelocytic leukemia
by: Sudip D. Thakar, et al.
Published: (2021-06-01) -
Multimodal imaging characteristics of acute macular neuroretinopathy
by: Kumar Saurabh, et al.
Published: (2019-01-01)